key: cord-0969503-fq25pbqr
authors: Favresse, Julien; Bayart, Jean-Louis; David, Clara; Dogné, Jean-Michel; Douxfils, Jonathan
title: Nucleocapsid Serum Antigen Determination in SARS-CoV-2 Infected Patients Using the Single Molecule Array Technology and Prediction of Disease Severity
date: 2022-01-21
journal: J Infect
DOI: 10.1016/j.jinf.2022.01.023
sha: 7dfeafd67b9ca0e748dd7a4ba3cf627e90c227d9
doc_id: 969503
cord_uid: fq25pbqr

nan

We read with interest the paper of Li et al. reporting serum amyloid A (SAA) as a possible biomarker to evaluate the severity of coronavirus disease and progression.(1) They found that the ratio of SAA to lymphocyte (SAA/L) was significantly increased in critically severe patients. A recent meta-analysis also supports the use of this biomarker to assess the severity of the disease although a high heterogeneity among the studies was reported. (2) Other biomarkers have also been linked with disease severity and complications and we would like to share our data regarding the association between the level of SARS-CoV-2 nucleocapsid antigens and the severity of COVID-19.

Eighty-one unvaccinated patients with documented nasopharyngeal (NP) RT-PCR positive for SARS-CoV-2 (eSwab tubes; Copan Italia, Brescia, Italy) for which a serum sample (BD SST II Advance ® ; Becton Dickinson, NJ, USA) was obtained within 12 hours of NP sampling were included. The median delta collection time was 1 minute (10 th -90 th percentiles: -74 to 183 minutes). Thirty-six patients (44.4%) were women (median age = 77 years, min-max = 20-97) and 45 (55.6%) were men (median age = 76.5 years, min-max = 33-94). Eighteen patients were categorized as asymptomatic (WHO score of 1), 6 as symptomatic ambulatory (Figure 1B) . Other studies found a clinical sensitivity ranging from 85.2% to 93.0% (5-7) in patients that developed symptoms up to maximum two weeks. The clinical sensitivity increased to 94.2% to 100% considering samples collected within the first days since the onset of symptoms. After 2 weeks, the clinical sensitivity progressively decreased to values comprised between 43.2% to 74.5%.(3, 5-7) Given that the peak of N antigens is reached after 7 days, as for the viral load in NP samples, (8) and that a continuous decline is observed afterwards, the timing since symptoms is therefore essential for the evaluation of antigenemia.

Interestingly, we found that N antigen levels were significantly increased in severe patients (median = 7,673 pg/mL) compared to moderately affected (351.6 pg/mL, p = 0.0174) and asymptomatic patients (median = 4.6 pg/mL, p < 0.0001). Moderate patients also had significantly higher antigen levels compared to asymptomatic subjects (p = 0.0030) (Figure   2A ). Using ROC curve analysis for the classification of hospitalized (WHO score of 4 to 10) versus non-hospitalized patients (WHO score of 1 to 3), a cut-off of 1,631.9 pg/mL was identified (sensitivity = 45.6%, specificity = 95.8%; AUC = 0.76, p < 0.0001) (Figure 2B In conclusion, sensitive N antigen determination in serum provides a valuable marker for COVID-19 diagnosis and evaluation of severity. Further studies with more patients are needed to complement our data. A better discrimination of N antigen levels based on the days since symptoms as well as correlation with antibody seropositive are also needed. 

Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis

Serum amyloid A concentrations, COVID-19 severity and mortality: An updated systematic review and meta-analysis

N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection

Cell-based Culture Informs Infectivity and Safe De-Isolation Assessments in Patients with Coronavirus Disease

Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19

Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives

Diagnostic Value of Nucleocapsid Protein in Blood for SARS-CoV-2 Infection. Clinical chemistry

Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19)

Daily monitoring of viral load measured as SARS-CoV-2 antigen and RNA in blood, IL-6, CRP and complement C3d predicts outcome in patients hospitalized with COVID-19. Clinical chemistry and laboratory medicine : CCLM / FESCC

Serum levels of SARS-CoV-2 nucleocapsid antigen associate with inflammatory status and disease severity in COVID-19 patients

The authors would like to thank the technical teams from the laboratories